1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. CELL BANKING OUTSOURCING MARKET BY BANK TYPE
5.1. Introduction
5.2. Master Cell Bank
5.3. Working Cell Bank
6. CELL BANKING OUTSOURCING MARKET BY CELL TYPE
6.1. Introduction
6.2. Stem Cell
6.3. Non-Stem Cell
7. CELL BANKING OUTSOURCING MARKET BY END-USER
7.1. Introduction
7.2. Pharmaceutical & Biotech Companies
7.3. Academic & Research Institutes
7.4. Others
8. CELL BANKING OUTSOURCING MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Bank Type
8.2.2. By Cell Type
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Bank Type
8.3.2. By Cell Type
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Bank Type
8.4.2. By Cell Type
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. Germany
8.4.4.2. France
8.4.4.3. United Kingdom
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Bank Type
8.5.2. By Cell Type
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Bank Type
8.6.2. By Cell Type
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. China
8.6.4.2. India
8.6.4.3. Japan
8.6.4.4. South Korea
8.6.4.5. Indonesia
8.6.4.6. Thailand
8.6.4.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Sartorius AG
10.2. Cryosite Limited
10.3. Charles River Laboratories Inc.
10.4. Cryo-Cell International, Inc
10.5. GBI Biomanufacturing
10.6. Lonza Group
10.7. SGS SA
10.8. WuXi AppTec
10.9. Eurofins Scientific
10.10. SK Pharmteco Inc
10.11. Biofortuna Limited
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES